Objective: Despite the well-acknowledged problem of poor adherence to antipsychotic (AP) medication, long-acting injectables (LAIs) that could improve adherence are underused in Canada. Attitudes concerning LAIs among patients and psychiatrists may contribute to this underuse. Our objective was to investigate perceptions of and attitudes toward LAIs among patients in Canada.
Clinical Implications
• Improving perceptions about LAI APs and subsequently increasing their use may require that they be presented as one of the possible medication choices at every phase of the illness, including early in the course of treatment. More effective methods of imparting knowledge about LAI APs may be necessary to improve their use.
• To improve patient acceptance of LAIs, systemic changes may have to be implemented to reduce the inconvenience and costs involved with receiving LAIs.
• Patients do not necessarily have negative attitudes toward taking their APs in injection form.
Limitations
• A relatively small sample, from a limited range of treatment settings, was recruited, which may limit the generalizability of the results. However, an attempt was made to include younger and older, French-and English-speaking patients from early and later stages of psychoses, and from 4 provinces in Canada.
• Information regarding years since onset of illness was missing for focus group patient participants from 1 of the 4 sites.
A ntipsychotics are essential for the effective management of schizophrenia and other psychoses, for treatment in the acute phase and for relapse prevention. 1 Medication nonadherence is highly prevalent (range, 10% to 88%) among patients with schizophrenia and related psychotic disorders, with median rates ranging from 41% to 55%. [1] [2] [3] This poor medication adherence is associated with significant personal, social, and economic costs. Specifically, poor adherence has been linked with higher levels of residual symptoms, higher risk and rate of relapse, increased hospitalization rates, lower rates of remission of positive symptoms, longer time to remission in the FEP, greater mortality and morbidity from multiple causes, poorer quality of life, and impaired social and independent functioning. 1, [3] [4] [5] [6] [7] Often seen as a dichotomous variable, adherence actually ranges between complete nonadherence (0%) and complete adherence (100%). Partial adherence can stem from factors such as lack of a daily routine, forgetfulness, ambivalence, and cognitive deficits, 1 and even relatively brief partial nonadherence (2 to 4 weeks) to oral APs has been associated with a significant risk of relapse among patients with recentonset schizophrenia. 8 In a recent reveiw, Barkhof et al 9 found no overwhelming evidence supporting any single intervention to improve medication adherence and attributed this, in part, to the heterogeneity of factors contributing to nonadherence.
Une étude qualitative des expériences avec les antipsychotiques injectables à action prolongée et des perceptions à ce sujet : 1re partie -Perspectives des patients
Objectif : Malgré le problème largement reconnu de la mauvaise observance des antipsychotiques (AP), les injectables à action prolongée (IAP) qui pourraient améliorer l'observance sont sous-utilisés au Canada. Les attitudes à l'égard des IAP chez les patients et les psychiatres peuvent contribuer à cette sous-utilisation. Notre objectif était d'enquêter sur les perceptions et les attitudes des patients à l'égard des IAP au Canada.
Méthode : Des groupes de discussion ont été formés de 34 patients ayant reçu un diagnostic de psychose du spectre de la schizophrénie dans 4 provinces canadiennes. Les groupes de discussion portaient sur les expériences avec les AP IAP et les attitudes à leur égard. Les séances ont fait l'objet d'un enregistrement sonore et ont été transcrites textuellement, et ces transcriptions ont été codées à l'aide d'une combinaison de méthodes déductives et inductives.
Résultats :
Quatre thèmes se sont dégagés : conscience et connaissance des IAP; perceptions des IAP; considérations concernant le coût et la commodité; et les questions liées au contexte coercitif dans lequel les IAP sont souvent prescrits. Neuf patients n'avaient jamais entendu parler des IAP, et d'autres ont déclaré ne pas avoir compris lorsqu'on a discuté avec eux des IAP. Les patients avaient habituellement entendu parler des IAP dans un contexte soit de coercition, soit de non-observance des médicaments. Les patients avaient des perceptions positives et négatives à l'égard des IAP. Les perceptions positives étaient axées sur la prévention de la rechute et l'effort réduit pour maintenir l'observance, et les perceptions négatives portaient sur les coûts financiers et la complication des rendezvous pour recevoir les injections.
Conclusion : Afin d'accroître l'utilisation des IAP, il faut aborder certaines questions, notamment l'insuffisance de l'information donnée aux patients, l'élément de coercition présent dans l'instruction aux IAP, les obstacles pratiques à la prise d'IAP par les patients, et les perceptions subjectives négatives à l'égard des IAP.
Therefore, multiple strategies, including LAI APs, are needed to enhance medication adherence in psychosis.
Despite FGA LAIs having been found to reduce the need for hospital treatment among patients, compared with those receiving typical oral APs, 10, 11 the introduction of SGAs that produced fewer neurological side effects led to a move away from prescribing depot typical medications to oral atypical medications. 12, 13 Interestingly, the assumption that much nonadherence was associated with the neurological side effects of typical APs has not been supported by evidence. 1, 2 The 2001 introduction of the SGA LAI, RLAIs, has rekindled interest in LAI APs.
There is considerable evidence suggesting significantly higher adherence rates with LAI APs, compared with oral APs. 10, 14 By greatly simplifying medication regimens and allowing easier tracking of adherence, LAIs can be effective in tackling partial adherence, particularly when unintentional. Physicians, often underestimating nonadherence, [15] [16] [17] may also misidentify nonadherent or partially adherent patients as being nonresponsive to particular medications. Therefore, LAIs can be useful (albeit limitedly) in separating response and adherence issues. The evidence for effectiveness of SG LAIs, in particular, and their underuse in Canada have been reviewed in the first chapter of this supplement (see Chapter 1; Manchanda et al 18 ).
Patients' and treatment providers' attitudes toward LAIs may influence both the psychiatrists' LAI prescribing habits and their acceptance among patients. 17, [19] [20] [21] A comprehensive literature review 22 has reported that 5 out of 6 reviewed studies found a patient preference for LAIs, compared with oral agents, in those receiving LAIs, while a more recent review 23 of a larger number of studies concluded that LAIs are often seen negatively by patients except for those already prescribed an LAI. To our knowledge, no study examining attitudes toward LAI APs has been conducted in Canada. Also, most studies have used surveys and (or) questionnaires, and only one study (to our knowledge) 24 has focused on subjective perceptions about and personal experiences with LAIs. From an open-ended interview study in Sweden, Svedberg et al 24 concluded that patients on depot treatment expressed favourable attitudes, based on painful memories of lost control during previous episodes. Therefore, our study sought to explore how patients with psychosis view LAI APs using focus group methodology.
Method
Focus group methodology was chosen for its potential to clarify diverse group norms and meanings 25 and to develop a complex, complete, and nuanced picture of the issue. 26, 27 The discursive dynamics involved in focus groups can also yield a more complex and synergistic co-construction of meaning. 28, 29 
Focus Group Participants
Focus groups were conducted in Halifax, Nova Scotia; Quebec City, Quebec; London, Ontario; and Victoria, British Columbia in 2010. The study was approved by the relevant ethics committees at each site. Coauthors (Dr Roy, Dr Tibbo, Dr Manchanda, and Dr Williams) helped in recruitment of patients by publicizing or discussing the study with relevant professionals and patients. Patients were selected if they had a diagnosis (Diagnostic and Statistical Manual of Mental Health, Fourth Edition) of a schizophrenia spectrum psychosis (clinical diagnosis provided by treating psychiatrist), were receiving outpatient treatment at the time of recruitment, and were considered stable enough to participate by the recruiting psychiatrist (Dr Roy, Dr Tibbo, Dr Manchanda, and Dr Williams). At each site, specific attempts were made to recruit younger and older patients; patients in early and later stages of psychosis; and patients who were or had been prescribed an LAI and those who had never been prescribed an LAI. Written informed consent was obtained and patients were compensated (Can$50) for reasonable out-of-pocket expenses (for example, transportation costs) and their time.
The final sample (clinical and demographic information in Table 1 ) included 34 patients-8 from Halifax, 7 from Quebec City, 10 from London, and 9 from Victoria. 
Focus Group Sessions
A focus group interview with broad, open-ended questions regarding attitudes toward and experience with LAIs was developed. Patients also filled in worksheets to indicate whether they had ever been prescribed LAIs and to list advantages and disadvantages of LAIs. The patient focus groups lasted for 2 hours, on average. Interviews were conducted by 2 trained facilitators in French in Quebec and in English at the other sites.
Analysis
The focus group discussions were recorded and fully transcribed (and, in the case of the Quebec group, translated from French into English). The method of analysis 30 incorporated both the deductive approach outlined by Crabtree and Miller 31 and the inductive approach advocated by Boyatzis. 32 Following Boyatzis, coding involved recognizing important moments and encoding them, thus allowing the data to suggest themes and categories. The deductive approach involved the systematic analysis of transcribed data by the sorting of verbatim material into a template based on the specific questions for which they had been probed. The coding system was continuously revised during analysis. Two of the coauthors (Dr Iyer and Dr Malla) were involved in the coding of the transcripts. The final coding system and the allocation of blocks of text to particular themes were arrived at by discussion and consensus.
Focus groups, examining attitudes toward and prescribing patterns around LAIs, were also conducted with physicians at the same sites. The results from these are presented in an accompanying publication (see Part II; Chapter 3; Iyer et al 33 ).
Results
All the analyzed data from the transcripts could be resolved into 4 main themes: knowledge about LAIs; perceptions about LAIs; cost and convenience considerations; and issues arising from the coercive context under which LAIs were often prescribed. Each category is described below, along with illustrative quotes. The patient-identified advantages and disadvantages of LAIs appear in Table 2 , sorted by whether patients had prior LAI experience. I chose not to inject because of lack of information. I didn't have access to patient testimonials or really the side effects weren't explained very well to me as much as other medications. It just seemed a lot more scary at the time.
Awareness of and Knowledge About LAIs
For most patient-participants, LAIs had not been introduced as an option at the beginning or even early in the course of treatment. One patient put it thus:
Um, I would have liked to have been put on injectable drugs years earlier, cause otherwise I wouldn't had suffered more, I had another episode . . . I don't know if they would have been available earlier, but I would have preferred that because I would still be working these days.
Most patient participants reported that it was their psychiatrist who had initially discussed LAIs with them.
Others had first heard about LAIs from their nurses, social workers, magazines and (or) pamphlets, and a roommate and (or) peer who had been prescribed an LAI. Two patients specifically mentioned the role of their parents in discussing and encouraging them to try LAIs. One said, Yeah, I think I lacked the awareness initially to understand the benefits that I could derive from taking it, but I think it [took] my parents . . . and their tearful, fearful eyes . . . for me to understand it, to say ok I'll take it, and I'll take it responsibly . . . and I eventually got better and I've done a little research on it and I'm happy to be on it.
Finally, one patient's awareness of LAIs came from participating in a research study that prescribed pills to onehalf of a sample and LAIs to the rest. A few patients cited feelings of not being in control as the reason for which they had not taken or would not take an LAI. Below, 2 patients describe feeling more in charge with pills than they would with injectables:
Perceptions About LAIs
With the needle, I'm dependent on going to the appointments. I'm not sure if it's a real concern, but when I take my 
Threat and External Control Issues
Eight out of 14 patients who were or had been on LAIs were initiated on LAIs either via a CTO (often after several episodes of nonadherence followed by a relapse and [or] hospitalization) or during an involuntary hospital admission. Specifically, 3 out of 14 patients (21.43%) were initiated on LAIs during an involuntary admission (2 of these were later put on a CTO) and 5 out of 14 patients (35.71%) were taking, or had taken, LAIs because of a treatment order. Some of them spoke about working through initial feelings of anger and disapproval toward the LAIs after perceiving their significant advantages. Here, a patient expresses gratitude that she "was persuaded" to go on LAIs, "Um, if I hadn't been persuaded, I probably would still be noncompliant, so I'm thankful I was persuaded." Others still retained negative feelings about having been coerced to take medications. One such patient said,
The only time I was ever [on an] injectable . . . was when I was hospitalized, for the psychiatric assessment or whatever, then I get away from the hospital and I get away from psychiatrists and I dropped my meds all the time. My experience wasn't good, I didn't learn from anyone, it was just something that was forced on me. I didn't have a choice in the matter . . . and when there was a choice, I chose not to take it.
Such coercion may also prevent some patients from assenting to LAIs, as evinced by this quotation:
Well, for me, when I was given the option, I kind of felt like someone [would be] looking over my shoulder with the injectable, like it wasn't my choice.
The initiation of LAIs among 6 out of 14 patients (42.86%) involved neither a CTO nor involuntary hospitalization. Even among these voluntary initiates, 2 had been presented with an ultimatum or a threat of being placed on a CTO if they refused LAIs ("It was a bit hard. I didn't have much choice. It was take this or we're going to court"). Others reported that it was brought up in the context of their nonadherence, "For me, it was because I stopped."
Other reasons for voluntarily choosing LAIs included persuasion or pressure by family and (or) treatment team ("took injections to get people off my back") and convenience ("I decided to start taking the shot just because you know it would help with taking it on time every single month, and, uh, it was just added to the convenience"). One patient felt that LAIs were an "intelligent" option.
Convenience and Cost Considerations
One of the 2 pragmatic obstacles to taking LAIs identified by the patients was the inconvenience of frequent (usually fortnightly) clinic appointments, often during the typical work or school day. The following quotes illustrate this point:
You have the impression of losing all day.
What I don't like about the long-acting injectables is you have to go and get them during clinical hours, like Monday through Friday, and for me, like, I would rather not tell an employer that I have to get an injection, and go in and get on a Saturday . . . or a Sunday, and that's not really an option.
I've had to skip a lot of classes to get my injection, and when I prioritize, too, my education is extremely important to me but not as important as my health, so I'm forced to choose . . . it's not the most convenient time . . . in the 9 to 5 type of society that we live in. And it's just, there's an overlap there, I think it's not necessarily beneficial for the patient.
The financial costs of LAIs were often discussed as another obstacle, particularly at sites outside Quebec.
Consider the following quotes:
The injectable is more expensive than the pills. It's like seven hundred dollars a month.
It's not cheap . . . it's an undue burden upon them [referring to his parents who were covering the cost of his LAIs].
Pragmatic inconveniences were mentioned by a few patients as reasons for eschewing the LAI option. The following dialogue is exemplary: Factors suggested by patients as conducive to increasing LAI uptake included LAI cost reduction; flexible clinic hours (for example, evening and weekend); the availability of time ranges instead of fixed times for LAI appointments; and the option of being injected at home ("Because if you calculated that 1 nurse travels for 15 patients, it means less travel than 15 patients who travel for 1 nurse"). The need for removing pragmatic barriers was summed up beautifully by one patient who said, "To facilitate access means to facilitate treatment."
Discussion
Our key findings under the 4 main themes were as follows: [34] [35] [36] It would also be consistent with the emerging idea that LAIs may have clinical utility, even in the early stages of psychosis. [37] [38] [39] Presented early on, the LAI option would not be associated only with more difficult (for example, a relapse following suspected nonadherence) or coercive (for example, CTO being sought) junctures of treatment. This is also likely to improve patient perceptions and acceptance of LAIs. Clinicians may benefit more from exploring patients' subjective perceptions of LAIs rather than by basing treatment decisions on their own assumptions thereof. Our finding that some patients chose LAIs because they saw it as intelligent or convenient is consistent with the second cluster of patients for whom LAIs were appropriate according to Heres et al. 40 They described this cluster as having a "high level of insight, openness to drug treatment and profound knowledge about the disease" and contrasted it with the first cluster of patients with "episodes of noncompliance and relapses in the past." 40, p 1987 Concerted efforts are needed to address potentially malleable pragmatic factors that impede LAI acceptance. For instance, clinics could offer weekend appointments, home visits, or ranges of time for administering injections. address this issue because even minor changes in costs to patients are known to impact adherence. [41] [42] [43] Our study has several limitations. We used a relatively small sample (4 groups) from a limited range of treatment settings and with relatively higher rates of prior experience with LAIs than is found in the general patient population. It is possible that patients who consented to participate were likelier to be medication-adherent and less likely to be on CTOs. The number of focus groups was decided prestudy; thus sample size was not determined by "point of saturation" 44, p 2 considerations. These sampling issues limit the generalizability of our findings. However, an attempt was made to include younger and older patients, patients from early and later illness stages, and patients from 4 Canadian provinces. Information regarding years since illness onset was missing for participants from one site. Specific probing on certain topics like the fear of needles and how the cost of LAIs is borne (for example, state insurance, private insurance, out of pocket, and family support) would have been beneficial. Despite these limitations, the use of focus group methodology yielded important insights that may have been missed with exclusively questionnaire and (or) survey methodology. These insights have implications for addressing the issue of underuse of LAIs, which, in turn, can help improve medication adherence in people with schizophrenia and other psychoses.
